SHANGHAI, July 8, 2020 /PRNewswire/ -- Asieris
Pharmaceuticals (Asieris), a China-based biotech company with global
aspirations to discover, develop and commercialize innovative drugs
for the treatment of genitourinary tumors and related diseases,
announced today it has received Clinical Trial Approval (CTA) from
China's National Medical Products
Administration (NMPA) for the global, multi-centered
Phase III clinical trial of its photodynamic drug-device
combination product, APL-1702 (Cevira®), which is being
developed for the non-surgical treatment of high-grade cervical
dysplasia (HSIL).
In addition to China, Asieris
has concurrently initiated this global pivotal trial in
the United States, Germany, Romania, Hungary, Russia, Ukraine and other European countries. Data
from this trial will support the market approval applications in
China, the United States, the European Union, and
other countries.
Please read the full release here.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/photocure-s-partner-asieris-received-china-nmpa-s-approval-to-start-a-global-phase-iii-clinical-tria,c3151109
The following files are available for download:
https://mb.cision.com/Main/17498/3151109/1276735.pdf
|
Release
|